Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Sun Yat-sen University · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
relapsed or refractory dlbcl, dlbcl, rituximab, chidamide, anti-pd-1 antibody, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 862429
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.